false 0001501989 0001501989 2025-01-30 2025-01-30

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 30, 2025

 

 

CYTOMX THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-37587   27-3521219

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

151 Oyster Point Blvd

Suite 400

South San Francisco, California

   94080
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (650) 515-3185

Former Name or Former Address, if Changed Since Last Report: N/A

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.00001 par value per share   CTMX   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 30, 2025, Jeffrey Landau, Senior Vice President, Chief Business Officer, and Head of Strategy, of CytomX Therapeutics, Inc. (the “Company”) and the Company agreed that Mr. Landau’s employment by the Company would terminate, effective February 7, 2025. The Company will enter into a Separation Agreement with Mr. Landau (the “Separation Agreement”) that provides for economic payments to Mr. Landau consistent with the terms of his Amended and Restated Severance and Change of Control Agreement effective as of April 12, 2021, the form of which was filed as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed on August 8, 2023. The Separation Agreement also will include a general release of claims against the Company.

The foregoing description of the Separation Agreement is qualified in its entirety by reference to the full text of the Separation Agreement is expected to be filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ending December 31, 2024.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: February 3, 2025     CYTOMX THERAPEUTICS, INC.
    By:  

/s/ Lloyd Rowland

      Lloyd Rowland
      Senior Vice President, General Counsel
v3.25.0.1
Document and Entity Information
Jan. 30, 2025
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001501989
Document Type 8-K
Document Period End Date Jan. 30, 2025
Entity Registrant Name CYTOMX THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-37587
Entity Tax Identification Number 27-3521219
Entity Address, Address Line One 151 Oyster Point
Entity Address, Address Line Two Blvd
Entity Address, Address Line Three Suite 400
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (650)
Local Phone Number 515-3185
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.00001 par value per share
Trading Symbol CTMX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
CytomX Therapeutics (NASDAQ:CTMX)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025 CytomX Therapeutics 차트를 더 보려면 여기를 클릭.
CytomX Therapeutics (NASDAQ:CTMX)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025 CytomX Therapeutics 차트를 더 보려면 여기를 클릭.